Late graft failure after kidney transplantation as the consequence of late versus early events

Robert S. Gaston, Ann Fieberg, Lawrence Hunsicker, Bertram L. Kasiske, Robert Leduc, Fernando G. Cosio, Sita Gourishankar, Joseph Grande, Roslyn B. Mannon, David Rush, J. Michael Cecka, John Connett, Arthur J. Matas

Research output: Contribution to journalArticlepeer-review

35 Scopus citations

Abstract

Beyond the first posttransplant year, 3% of kidney transplants fail annually. In a prospective, multicenter cohort study, we tested the relative impact of early versus late events on risk of long-term death-censored graft failure (DCGF). In grafts surviving at least 90 days, early events (acute rejection [AR] and delayed graft function [DGF] before day 90) were recorded; serum creatinine (Cr) at day 90 was defined as baseline. Thereafter, a 25% rise in serum Cr or new-onset proteinuria triggered graft biopsy (index biopsy, IBx), allowing comparison of risk of DCGF associated with early events (AR, DGF, baseline serum Cr >2.0 mg/dL) to that associated with later events (IBx). Among 3678 patients followed for 4.7 ± 1.9 years, 753 (20%) had IBx at a median of 15.3 months posttransplant. Early AR (HR = 1.77, P <.001) and elevated Cr at Day 90 (HR = 2.56, P <.0001) were associated with increased risk of DCGF; however, later-onset dysfunction requiring IBx had far greater impact (HR = 13.8, P <.0001). At 90 days, neither clinical characteristics nor early events distinguished those who subsequently did or did not undergo IBx or suffer DCGF. To improve long-term kidney allograft survival, management paradigms should promote prompt diagnosis and treatment of both early and later events.

Original languageEnglish (US)
Pages (from-to)1158-1167
Number of pages10
JournalAmerican Journal of Transplantation
Volume18
Issue number5
DOIs
StatePublished - May 2018

Bibliographical note

Funding Information:
This work was supported between 2005 and 2012 via a grant from the National Institutes of Health (5U01A1058013), and since 2013 by unrestricted grants from Astellas, Bristol-Myers Squibb, Novartis, Pfizer, and Sanofi-Aventis.

Publisher Copyright:
© 2017 The American Society of Transplantation and the American Society of Transplant Surgeons

Keywords

  • chronic allograft nephropathy
  • clinical research/practice
  • delayed graft function (DGF)
  • kidney (allograft) function/dysfunction
  • kidney transplantation/nephrology
  • rejection: acute

Fingerprint

Dive into the research topics of 'Late graft failure after kidney transplantation as the consequence of late versus early events'. Together they form a unique fingerprint.

Cite this